President Trump announced Monday that his administration has signed agreements with nine additional pharmaceutical companies to provide discounted medications to state Medicaid programs. The move is part of a "most-favored-nation" drug pricing policy, which aims to match U.S. drug costs with the lower prices paid by other developed nations. During an announcement at the Oval Office, the president stated that 26 companies now participate in these voluntary agreements, representing approximately 90% of the domestic pharmaceutical market.
The policy framework for these deals was established through a series of executive actions. President Trump signed an executive order on May 12, 2025, directing the administration to align U.S. drug prices with international benchmarks. This was followed by letters sent to manufacturers on July 31, 2025, and the launch of TrumpRx, a website for direct-to-consumer discounted sales, on February 5, 2026. The White House reported that 17 companies had already entered similar agreements prior to Monday’s announcement.
The nine new firms participating in the deal include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. According to the White House, these manufacturers have also committed to investing $19.6 billion in U.S. manufacturing. These agreements follow a separate group of deals announced on December 19, 2025, with nine major firms including Amgen, Merck, and Gilead Sciences. The administration projects that the total agreements across all participating companies will save Americans more than $600 billion.
The agreements affect Medicaid enrollees across every U.S. state, as the participating companies have agreed to provide access to most-favored-nation pricing for these government-funded programs. For individual consumers using the TrumpRx platform, the administration reports substantial price changes for specific medications from the December 19, 2025, group of firms. For example, the price of the cholesterol medication Repatha was reduced from $573 to $239, and the type two diabetes drug Jentadeuto fell from $525 to $55. A patient requiring the blood thinner Plavix would see the price drop from $756 to $16, while insulin products from Sanofi are listed at $35 for a one-month supply.
The scale of the initiative involves at least 26 companies and is projected by the administration to save more than $600 billion over a "very short period of time." Beyond direct price reductions, the December 19 group of firms committed to collectively invest $150 billion in U.S. manufacturing. Additionally, that earlier agreement established a precedent for national health security through the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), with companies like GSK and Bristol Myers Squibb donating active ingredients such as apixaban and albuterol to ensure emergency supplies.
The administration has also addressed international drug pricing, reaching an agreement with the United Kingdom on December 1, 2025, that will increase the net price of new prescription drugs there by 25%. This move is intended to ensure other nations contribute more to the cost of pharmaceutical innovation. Moving forward, the White House expects the remaining 10% of the domestic market to eventually join the voluntary pricing agreements. Consumers can currently access reported discounts through the TrumpRx website, while the manufacturing investments and API donations were scheduled for the "near term."